Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma

Clinical Transplantation

Volumn 21, Issue 3, 2007, Pages 337-343

  Yun, Tak ^a   Lee, Keun Wook ^a   Song, Eun Gi ^a   Na, Im Il ^a   Shin, Hyun Chun ^a   Yoon, Sung Soo ^a   Park, Seon Yang ^a   Kim, Byoung Kook ^a   Lee, Jung Hee ^b   Choi, Seong Jun ^b   Lee, Je Hwan ^b   Lee, Kyoo Hyung ^b  

^a Seoul National University Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Non myeloablative stem cell transplantation; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 2; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; FEMALE; GRAFT INFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LYMPHOCYTE TRANSFUSION; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; SOUTH KOREA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; CARCINOMA, RENAL CELL; CHIMERISM; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 34248165054     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00646.x     Document Type: Article

References (28)

1. De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: A phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996: 37: 491.
2. Mertens WC, Eisenhauer EA, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994: 5: 185.
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000: 163: 408.
4. Walpole ET, Dutcher JP, Sparano J et al. Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. J Immunother 1993: 13: 275.
5. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995: 22: 42.
6. Fisher RI, Coltman CA Jr, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 1988: 108: 518.
7. Ilson DH, Motzer RJ, Kradin RL et al. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 1992: 10: 1124.
8. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998: 338: 1272.
9. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000: 343: 750.
10. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000: 111: 6.
11. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990: 76: 2462.
12. Dazzi F, Goldman J. Donor lymphocyte infusions. Curr Opin Hematol 1999: 6: 394.
13. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002: 99: 4234.
14. Pedrazzoli P, Da Prada GA, Giorgiani G et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: A pilot study in patients with refractory malignancies. Cancer 2002: 94: 2409.
15. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results. J Clin Oncol 2002: 20: 2017.
16. Hentschke P, Barkholt L, Uzunel M et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003: 31: 253.
17. U enoNT, Cheng YC, Rondon G et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003: 102: 3829.
18. Blaise D, Bay JO, Faucher C et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004: 103: 435.
19. Artz AS, Van Besien K, Zimmerman T et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant 2005: 35: 253.
20. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994: 7: 85.
21. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993: 260: 1317.
22. Iliopoulos O, Kaelin WG Jr. The molecular basis of von Hippel-Lindau disease. Mol Med 1997: 3: 289.
23. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997: 17: 5629.
24. Ananth S, Knebelmann B, Gruning W et al. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999: 59: 2210.
25. Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R. Second-line strategies for metastatic renal cell carcinoma: Classics and novel approaches. J Cancer Res Clin Oncol 2006: 132: 137.
26. van Spronsen DJ, Mulders PF, De Mulder PH. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2005: 55: 177.
27. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006: 24: 16.
28. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005: 23: 7889.